Advanced

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update

Gronwald, J ; Tung, N ; Foulkes, WD ; Offit, K ; Gershoni, R ; Daly, M ; Kim-Sing, C ; Olsson, Håkan LU ; Ainsworth, P and Eisen, A , et al. (2006) In International Journal of Cancer 118(9). p.2281-2284
Abstract
Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of similar to 80%, and following the first diagnosis the 10-year risk of contralateral breast cancer is similar to 30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is not clear whether there is a benefit in giving tamoxifen to women who have previously undergone an oophorectomy. Furthermore, the relative degree of protection in BRCA1 and BRCA2 carriers has not been well evaluated. We studied 285 women with bilateral breast cancer and a BRCA1 or BRCA2 mutation, and 751 control women with unilateral breast cancer and a BRCA1 or BRCA2 mutation in a matched case-control study. Control women were of similar age... (More)
Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of similar to 80%, and following the first diagnosis the 10-year risk of contralateral breast cancer is similar to 30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is not clear whether there is a benefit in giving tamoxifen to women who have previously undergone an oophorectomy. Furthermore, the relative degree of protection in BRCA1 and BRCA2 carriers has not been well evaluated. We studied 285 women with bilateral breast cancer and a BRCA1 or BRCA2 mutation, and 751 control women with unilateral breast cancer and a BRCA1 or BRCA2 mutation in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of breast cancer and had been followed for as long as the case for a second primary breast cancer. The history of tamoxifen use for treating the first breast cancer was compared between bilateral and unilateral cases. The multivariate odds ratio for contralateral breast cancer associated with tamoxifen use was 0.50 for carriers of BRCA1 mutations (95% CI, 0.304.85) and was 0.42 for carriers of BRCA2 mutations (95% CI, 0.17-1.02). The protective effect of tamoxifen was not seen among women who had undergone an oophorectomy (OR = 0.83; 95% CI, 0.242.89) but this subgroup was small. In contrast, a strong protective effect of tamoxifen was apparent among women who were premenopausal or who had undergone natural menopause (OR = 0.44; 95% CI, 0.27-0.65). (c) 2005 Wiley-Liss, Inc. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
BRCA2, oophorectomy, breast cancer, tamoxifen, BRCA1
in
International Journal of Cancer
volume
118
issue
9
pages
2281 - 2284
publisher
John Wiley and Sons Inc.
external identifiers
  • wos:000236567900022
  • pmid:16331614
  • scopus:33645675556
ISSN
0020-7136
DOI
10.1002/ijc.21536
language
English
LU publication?
yes
id
ad34a9da-47ba-436c-87aa-98a17a7a1685 (old id 414468)
date added to LUP
2016-04-01 12:38:03
date last changed
2020-09-23 02:58:39
@article{ad34a9da-47ba-436c-87aa-98a17a7a1685,
  abstract     = {Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of similar to 80%, and following the first diagnosis the 10-year risk of contralateral breast cancer is similar to 30%. It has been shown that both tamoxifen and oophorectomy prevent contralateral breast cancer, but it is not clear whether there is a benefit in giving tamoxifen to women who have previously undergone an oophorectomy. Furthermore, the relative degree of protection in BRCA1 and BRCA2 carriers has not been well evaluated. We studied 285 women with bilateral breast cancer and a BRCA1 or BRCA2 mutation, and 751 control women with unilateral breast cancer and a BRCA1 or BRCA2 mutation in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of breast cancer and had been followed for as long as the case for a second primary breast cancer. The history of tamoxifen use for treating the first breast cancer was compared between bilateral and unilateral cases. The multivariate odds ratio for contralateral breast cancer associated with tamoxifen use was 0.50 for carriers of BRCA1 mutations (95% CI, 0.304.85) and was 0.42 for carriers of BRCA2 mutations (95% CI, 0.17-1.02). The protective effect of tamoxifen was not seen among women who had undergone an oophorectomy (OR = 0.83; 95% CI, 0.242.89) but this subgroup was small. In contrast, a strong protective effect of tamoxifen was apparent among women who were premenopausal or who had undergone natural menopause (OR = 0.44; 95% CI, 0.27-0.65). (c) 2005 Wiley-Liss, Inc.},
  author       = {Gronwald, J and Tung, N and Foulkes, WD and Offit, K and Gershoni, R and Daly, M and Kim-Sing, C and Olsson, Håkan and Ainsworth, P and Eisen, A and Saal, H and Friedman, E and Olopade, O and Osborne, M and Weitzel, J and Lynch, H and Ghadirian, P and Lubinski, J and Sun, P and Narod, SA},
  issn         = {0020-7136},
  language     = {eng},
  number       = {9},
  pages        = {2281--2284},
  publisher    = {John Wiley and Sons Inc.},
  series       = {International Journal of Cancer},
  title        = {Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update},
  url          = {http://dx.doi.org/10.1002/ijc.21536},
  doi          = {10.1002/ijc.21536},
  volume       = {118},
  year         = {2006},
}